

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Barta, et al.

Serial No.:

10/088,989

Filing Date:

23 March 2002

Docket Number:

IDR0242-USA

Title:

PROCESS FOR THE PREPARATION OF

MYCOPHENOLIC ACID AND DERIVATIVES THEREOF

Assistant Commissioner for Patents Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97(c) hereby submit these publications for the Examiner's consideration which are known to them and considered warranting disclosure under 37 C.F.R. §1.56. A full copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this disclosure. However, please charge any necessary fees to our Deposit Account No. 50-0943.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

Simona A. Levi-Minzi, Ph.D.

Attorney for Applicants

Registration No. 43,750

Baker Norton Pharmaceuticals, Inc.

4400 Biscayne Boulevard Miami, Florida 33137

Tel.: (305) 575-6061 Fax.: (305) 575-6064

Date: 11/14/02

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on the date-indicated below.

Date: 114/02

Jarea G. Silberhorn

type a plus sign (+) inside this box -> | +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
blection of information unless it contains a valid OMB control number. r the Paperwork Reduction Act of 1995, no persons are required to response

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of

one to a concentration and an arrange in a state of the content of			
Complete if Known			
Application Number	10/088,989		
Filing Date	23 March 2002		
First Named Inventor	Barta		
Group Art Unit			
Examiner Name			
Attorney Docket Number	IDR0242-USA		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	JONES, D.F., et al., "Preparation and Antitumor Properties of Analogs and Derivatives of Mycophenolic Acid", J. Med. Chem. (1971), 14(4):305-11	
	2	SUZUKI, S., et al., "Antitumor Activity of Derivatives of Mycophenolic Acid", J. Antibiot. (1976), 29(3):275-85	
	3	SWEENEY, M.J., et al., "Experimental Antitumor Activity and Preclimical Toxicology of Mycophenolic Acid", Cancer Res. (1972), 32(9):1795-802	
	4	MCCORKINDALE, N.J., et al., "4-Methyl- and 7-methylphthalan-1-one Derivatives of Mycophenolic Acid", Tetrahedron(1981), 37(11):2131-6	
	5	JONES, D.F., et al., "Microbial Modification of Mycophenolic Acid", J. Chem. Soc. (1970), 12:1725-37	
-		•	

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.